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Abstract
Background: Reporting numbers needed to treat (NNT) improves interpretability of trial results.
It is unusual that continuous outcomes are converted to numbers of individual responders to
treatment (i.e., those who reach a particular threshold of change); and deteriorations prevented
are only rarely considered. We consider how numbers needed to treat can be derived from
continuous outcomes; illustrated with a worked example showing the methods and challenges.
Methods: We used data from the UK BEAM trial (n = 1, 334) of physical treatments for back pain;
originally reported as showing, at best, small to moderate benefits. Participants were randomised
to receive 'best care' in general practice, the comparator treatment, or one of three manual and/
or exercise treatments: 'best care' plus manipulation, exercise, or manipulation followed by
exercise. We used established consensus thresholds for improvement in Roland-Morris disability
questionnaire scores at three and twelve months to derive NNTs for improvements and for
benefits (improvements gained+deteriorations prevented).
Results: At three months, NNT estimates ranged from 5.1 (95% CI 3.4 to 10.7) to 9.0 (5.0 to 45.5)
for exercise, 5.0 (3.4 to 9.8) to 5.4 (3.8 to 9.9) for manipulation, and 3.3 (2.5 to 4.9) to 4.8 (3.5 to
7.8) for manipulation followed by exercise. Corresponding between-group mean differences in the
Roland-Morris disability questionnaire were 1.6 (0.8 to 2.3), 1.4 (0.6 to 2.1), and 1.9 (1.2 to 2.6)
points.
Conclusion: In contrast to small mean differences originally reported, NNTs were small and could
be attractive to clinicians, patients, and purchasers. NNTs can aid the interpretation of results of
trials using continuous outcomes. Where possible, these should be reported alongside mean
differences. Challenges remain in calculating NNTs for some continuous outcomes.
Trial Registration: UK BEAM trial registration: ISRCTN32683578.
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Measurement, and reporting, of clinical outcomes is cru-
cial to interpretation of randomised controlled trials. The
clinical importance of some outcomes, such as death, is
usually fairly clear. However, the clinical importance of
differences found in patient-reported continuous out-
comes, used to assess chronic disorders with variable
courses, such as low back pain, is often less clear. With
ever-larger trials, and meta-analyses of data from multiple
trials, we have the statistical power to demonstrate quite
small mean differences in these outcome measures that
are unlikely to have arisen by chance. However, the inter-
pretation of clinical importance remains problematic.
Summary statistics are, through statistical inference, appli-
cable to a population but results from these studies may
be less useful if we want to apply them to an individual.
For example, a 5 mm Hg change in blood pressure may be
important at a population level but of little relevance to
an individual. [1] For chronic disorders with variable
courses, the importance of small mean differences in con-
tinuous primary outcome measures of interest is less clear.
In early 2008 there was considerable media interest in the
UK in a meta-analysis of Selective Serotonin Reuptake
Inhibitors (SSRIs) that was reported as demonstrating that
these were not effective for the treatment of mild to mod-
erate depression http://news.bbc.co.uk/2/hi/health/
7263494.stm. [2] This paper has been very influential in
informing popular opinion about the use of Selective
Serotonin Reuptake Inhibitors, but it contrasts with an
earlier meta-analysis in which a similarly small standard-
ised effect size was reported (0.31 compared with 0.32)
and the authors concluded that these were superior to pla-
cebo. [3,4] It has been suggested that the discord between
conclusions stemmed from the use of a standardised effect
size to judge clinically important change. [4] Standardised
effect sizes, calculated as the between-group mean differ-
ence divided by the standard deviation at baseline, are one
approach to quantifying effect sizes in trials. Convention-
ally, 0.2 is considered small, 0.5 medium, and 0.8 large.
[5] This approach is widely used to define the magnitude
of changes in variables that can be readily observed.
Although there is generally a close relationship between
the standardised effect size and the proportion of partici-
pants who benefit from treatment, [6] this may not always
be the case. [7]
Thresholds of minimally important change (MIC) are
often used to judge the clinical importance of between-
group mean differences. However, simply dichotomising
group change as clinically important or not, does not tell
us how many individuals benefit from a treatment. Guyatt
and colleagues, [7] in 1998, demonstrated the usefulness
of assessing individual improvement by considering the
example of a trial with a mean effect of 0.25 units on a
continuous outcome scale, where the MIC for an individ-
ual is 0.5 units. This could represent a situation in which
the intervention has no effect in 75% of participants,
whilst 25% improve by 1.0 unit, implying that on average
one in every four participants treated would gain a clini-
cally important change; the number needed to treat
(NNT) is four. When only the mean difference is pre-
sented, which is half the magnitude of the MIC for an
individual, the intervention is likely to be interpreted as
ineffective. In contrast, an NNT of four suggests a highly
effective treatment.
How outcomes are presented, can have a substantial effect
on the interpretation of results. [8] However, many
authors still use only one method. Adding an estimate of
the NNT to gain, on average, one additional improve-
ment, may aid interpretation of trials with continuous
outcomes that are not intuitively understandable to
patients, clinicians, and purchasers; few authors do this.
Furthermore, for many common disorders, such as back
pain, depression, chronic fatigue, etc, it may be just as
important to prevent deteriorations as it is to promote
improvement; but few authors who report NNT consider
this. We aimed to explore practical challenges of using the
NNT to report a patient-reported continuous outcome in
a way that is clear to end-users and to explore its implica-
tions on the interpretation of a previously reported trial.
We report a re-analysis of data from the UK Back Pain
Exercise and Manipulation (UK BEAM) trial. [9] The larg-
est benefit from any of the treatments in UK BEAM was
1.87 points on the Roland-Morris disability questionnaire
(RMDQ), [10] at three months (a standardised mean dif-
ference of 0.47). This is smaller than the 2.5 point
between-group difference used for the sample size calcu-
lation and it has since been argued that, in light of this, the
benefits found in UK BEAM were not clinically important.
[11]
In this re-analysis we estimated the NNT for one patient to
gain a clinically important improvement and for one
patient to receive a benefit, defined as either an improve-
ment gained or deterioration prevented.
Methods
The UK BEAM trial is reported in detail elsewhere. [12]
Briefly, 1,334 participants with low back pain lasting for
more than four weeks were recruited from 181 practices in
the Medical Research Council General Practice Research
Framework. They were randomised between the following
interventions.
"Best care" in general practice (the "comparator" treatment) –
General practice teams were trained in "active manage-
ment" and provided patients with The Back Book.Page 2 of 10
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to nine exercise classes led by physiotherapists in commu-
nity settings. [15]
Spinal manipulation package – The UK chiropractic, osteo-
pathic, and physiotherapy professions agreed to use a
package of techniques, during eight sessions over 12
weeks. [16]
Combined treatment – Participants received six weeks of
manipulation followed by six weeks of exercise. Treat-
ments were those given to the manipulation only or exer-
cise only groups.
Outcome measures
UK BEAM's primary end point was the change in the
RMDQ from baseline to follow-up. [10] This 24-item
questionnaire measuring disability is one of the most
commonly used outcome measures in trials of back pain.
Scores range from 0 to 24; higher scores indicate greater
disability. A secondary outcome in UK BEAM was the par-
ticipants' global perception of change indicated on a
health transition question, a single item asking partici-
pants if they have experienced improvement or deteriora-
tion in their low back pain since beginning treatment.
[17] It has seven possible responses: 1. completely recov-
ered, 2. much improved, 3. slightly improved, 4. no
change, 5. slightly worsened, 6. much worsened, and 7.
vastly worsened. Follow-up was at four weeks, three and
12 months by postal questionnaire. Analyses were based
on mean differences between intervention groups and the
comparator treatment group. There were no differences
between groups at four weeks. Statistically significant pos-
itive results were observed for all three interventions at
three months, and for manipulation and combined treat-
ment at 12 months (Table 1). Our new analyses are
intended to aid interpretation of results unlikely to have
arisen by chance, not to change conclusions. We have
therefore focused on outcomes that were statistically sig-
nificant in the original analysis.
Individual improvement
The measurement precision of the outcome of interest is
important when judging the threshold for individual
change (whether it is deterioration or improvement). [18]
Clinicians are familiar with the concept of taking three
blood pressure measurement readings to assess whether
individuals are over a treatment threshold for hyperten-
sion; this limits measurement error due to the instru-
ment's imprecision and within person variation. The
measurement error, of any instrument, is inversely pro-
portional to the number of measurements; either repeated
measures on an individual or participants measured in the
group. The minimal detectable change is dependent on
measurement error, and thus depends on the number of
measurements. Trials can be designed so that the minimal
detectable change, is less than the threshold of minimally
important change ((MIC) i.e., a magnitude of change that
may be considered patient-important). [19-21] However,
at an individual level, there is evidence that the minimal
detectable change on the RMDQ is larger than the MIC.
[19,22-24] This leads to difficulty choosing a threshold by
which to judge individual improvement; adopting mini-
mal detectable change as a proxy for importance may not
lead to meaningful results; too few participants achieve
such large changes. One suggestion is that we measure
patients on multiple occasions before and after treat-
ment—this is similar to the approach for measuring
blood pressure. However, this may be impractical in stud-
ies of low back pain, where a questionnaire is used to
assess participants' change.
Similar MIC thresholds on the RMDQ have been identi-
fied from different populations using receiver operator
characteristic (ROC) curves. [19,23-27] In 2008, after
reviewing a mix of literature on the instrument's MIC and
minimal detectable change, a group of experts agreed five
RMDQ points represented an appropriate threshold by
which to judge individual improvement. [28] A further
challenge, is that the absolute magnitude of MIC on the
RMDQ may increase with baseline severity; [22,23,25,29]
Table 1: Roland-Morris score decrease in the UK BEAM trial
Net benefit from intervention
Group at three months (95% CI) at 12 months (95% CI)
Exercise 1.36** (0.63–2.10) 0.39 (-0.41–1.19)
Manipulation 1.57*** (0.82–2.32) 1.01* (0.22–1.81)
Combined treatment 1.87*** (1.15–2.60) 1.30** (0.54–2.07)
Adapted from UK BEAM BMJ 2004;329:1377–81
* Significant at 5% level
** Significant at 1% level
*** Significant at 0.1% levelPage 3 of 10
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participants is larger, or it could be wholly or partly, an
artifact due to regression to the mean. To account for this,
the group suggested a ≥ 30% improvement from baseline
as an alternative threshold for judging individual
improvement. [28] It is these values that we have used in
our analyses.
Population-specific comparison
To ensure that it was appropriate to apply the consensus
threshold of five points (change from baseline), we exam-
ined the MIC and the minimal detectable change in the
UK BEAM population. We used ROC curves, using the
transition question as the external criterion, to estimate
MIC. We categorised participants as improved if their
response to the transition question was 'completely recov-
ered' or 'much improved' [30] and defined MIC as the cut-
point on the RMDQ corresponding to the highest combi-
nation of sensitivity and specificity. [31] We estimated
minimal detectable change from the within person and
residual error of stable (neither improving nor deteriorat-
ing) patients' repeated measurements, between baseline
and four weeks (see Additional File 1). [20,32] The four
week follow-up data were not used in the original BEAM
analysis. We estimated minimal detectable change using
RMDQ data from those participants who indicated 'no
change' on the transition question at four weeks. To fur-
ther examine the stability of these participants, we tested
for a difference in their RMDQ scores, between baseline
and four weeks using Student's t test.
Guyatt et al [33] suggest that correlations of less than 0.5
between the change in health related quality of life
(HRQoL) score and the transition question, provide
grounds for doubting the construct validity of the transi-
tion question. Criticisms of using transition questions are
that the rating is likely to be highly correlated with the fol-
low-up health state, and that respondents may not cor-
rectly recall their initial health state (i.e., the baseline
score). To ensure that the transition question is measuring
change, and not merely reflecting current health states, a
correlation between baseline score and the transition
question, and follow-up score and the transition question
should ideally be present, equal, and opposite. [33] In
addition, in a linear regression model with follow-up
score entered as the initial explanatory variable, the base-
line score should explain a significant proportion of the
residual variance in the transition rating. [33] Thus, in
order to explore the validity of our transition question, we
calculated Pearson's correlation coefficient between base-
line and follow-up RMDQ scores, the change in RMDQ
score and the transition question, the baseline score and
the transition question, and the follow-up scores and the
transition question. Also, we constructed linear regression
models, in which the transition question was entered as
the dependent variable, and the follow-up scores as the
explanatory variables. Subsequently, we added the base-
line score to the models. Because of the large number of
comparisons, we considered a probability less than 0.01
statistically significant. We performed all analyses using
STATA version 10.
Calculating NNT
We calculated the NNT using the RMDQ for all compari-
sons with a statistically significant difference in the origi-
nal analysis. We used two methods of calculation; method
one, improvements gained, and method two, benefits
gained (improvements gained+deteriorations prevented).
Method one-additional improvements gained
We subtracted the proportion of patients who improved
in the control group from those who improved in the
intervention group (absolute risk reduction). We then
inverted this to obtain the NNT, and calculated 95% con-
fidence intervals using Bender's method, which is based
on Wilson scores. [34] The conventional method for cal-
culating 95% confidence intervals for NNTs is based on
the simple Wald method, which yields confidence inter-
vals that are, in many cases, too narrow. [34] The applica-
tion of Wilson score method improves the calculation and
presentation of the confidence intervals (See Additional
File 1). For the RMDQ we estimated improvements
gained using both a five-point reduction between baseline
and three months score, and a proportional reduction of
≥ 30% in the baseline score.
Method two-benefits gained
To incorporate deteriorations prevented, we calculated
the difference in the proportion of improvements minus
deteriorations in the intervention group and improve-
ments minus deteriorations in the control group. [35] We
then inverted the resulting absolute risk reduction to
obtain the NNT. We modified Bender's method of calcu-
lating 95% confidence intervals for NNT, to incorporate
the extra variance terms introduced through considering
both improvements and deteriorations (see Additional
File 1).
We used the same improvement thresholds as in method
one. As there is no consensus on thresholds for deteriora-
tion on the RMDQ, we sought to estimate MIC for deteri-
oration using ROC curves; using the transition question as
the external criterion. However, the value generated was
negative, implying that, on average, those who reported
deterioration had an improved RMDQ score; a paradox
that indicated the threshold was unsuitable for use. There-Page 4 of 10
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proportional increase in baseline score, as thresholds for
deterioration.
Results
At three months, complete RMDQ and transition ques-
tions were available on 1027/1334 (77%) and 882/1334
(66%) participants respectively. Figure 1 shows the distri-
butions of the RMDQ scores reduction; patents who
reported deterioration on the health transition question
had a mean decrease of 0.4 RMDQ points. At 12 months,
data were available on 994/1334 (75%) and 990/1334
(74%) participants; 640/1334 (48%) participants indi-
cated 'No change' at four weeks. The MIC and minimal
detectable change in our population were 4.0 (5.0 using
12 month data) and 8.1 points respectively. Participants
who indicated 'No change' at four weeks had a baseline
score of 8.5 RMDQ points (SD = 3.9) and a four week fol-
low-up score of 6.6 (SD = 4.6), P < 0.001).
Pearson's correlation coefficient between the baseline and
follow-up RMDQ scores was 0.52 (P < 0.001) at three
months and 0.50 (P < 0.001) at one year. The correlation
between the change in RMDQ score and the transition
question was 0.49 (P < 0.001) at three months, and 0.57
(P < 0.001) at one year. The correlations between the base-
line RMDQ score and the transition question were 0.17 (P
< 0.001) at three months and 0.22 (P < 0.001) at one year.
Correlations between the RMDQ follow-up scores and the
transition question were 0.57 (P < 0.001) at three months,
Score distributions of deteriorating, stable, and improving patientsFigure 1
Score distributions of deteriorating, stable, and improving patients. Figure one shows the distributions of RMDQ 
score decrease in patients who were classified as having deteriorated, remaining stable, or having improved on the transition 
question. One can see that patients who deteriorated (those who reported being 'much worse' or 'vastly worse') have a score 
change distribution with a mean close to zero (0.4). The MIC cut-off of 4.0 points and the consensus threshold of 5.0 points 
well separate improved patients from stable patients, in these data. Further research and debate on the MIC cut-off for deteri-
oration is needed.Page 5 of 10
(page number not for citation purposes)
BMC Medical Research Methodology 2009, 9:35 http://www.biomedcentral.com/1471-2288/9/35and 0.67 (P < 0.001) at one year. The mean RMDQ score
at baseline was 9.0 with an SD of 4.0, at three months it
was 5.5 with an SD of 5.0, and at one year it was 5.4 with
an SD of 5.2. In a linear regression model, the RMDQ fol-
low-up score at three months explained 33% of the vari-
ance in transition question rating at three months (β =
0.144, P < 0.001; the addition of the baseline score to the
model was significant and explained an extra 2% of the
variance (β = -0.056, P < 0.001). At one year, the RMDQ
follow-up score explained 45% of the variance in the tran-
sition question rating (β = 0.178, P < 0.001); the addition
of baseline score to the model was significant and
explained a further 2% of the variance (β = -0.058, P <
0.001).
Table 2 shows the numbers and proportion of partici-
pants who improved in each group using either five-
points or 30% change as thresholds marking responders
to treatment. Methods for calculating 'benefit' and
'improvement' produced similar NNTs using either five-
points or 30% change thresholds (Table 3). The ranked
effectiveness of the interventions followed the original
analysis (Table 1): the largest effect was seen in the com-
bined treatment group, and the smallest in the exercise
group.
At 12 months, effect sizes were smaller and similar in each
group (Table 3).
Discussion
These new analyses aid interpretation of the trial results.
Our analyses illustrate how the practical challenges of
incorporating deterioration and allowing for measure-
ment error might be overcome when basing NNTs on
patient-reported continuous outcomes. Nevertheless, we
were unable to develop a robust threshold for deteriora-
tion.
The striking finding here is that, in contrast to the original
analysis suggesting at best a small to moderate benefit
from the active interventions (Table 1), the NNTs to
achieve an improvement/benefit on the RMDQ were
small. Even for manipulation at one year, which had the
smallest of the statistically significant mean effects, the
NNT could be attractive to clinicians, patients, and pur-
chasers. Notably referring only five to six patients for the
manipulation package, on average will yield one addi-
tional improvement at three months, and, using the most
conservative of our estimates, eight to nine referrals, on
average will yield additional improvement at one year.
There is little difference in NNTs resulting from methods
one and two, suggesting that in this case, the active inter-
ventions had little effect on preventing or increasing dete-
riorations.
It is not ideal that our transition question ratings correlate
moderately with follow-up scores, and slightly but in the
Table 2: Numbers (%) of improved and deteriorated patients
Improved Stable Deteriorated
Three months
Best care
5 point reduction 62 (24) 181 (70) 13 (5)
30% change 125 (49) 99 (39) 32 (13)
Exercise
5 point reduction 82 (36) 138 (61) 5 (2)
30% change 135 (60) 81 (36) 9 (4)
Spinal manipulation
5 point reduction 125 (44) 148 (52) 14 (5)
30% change 193 (67) 63 (22) 31 (11)
Exercise and spinal manipulation
5 point reduction 117 (45) 135 (52) 7 (3)
30% change 185 (71) 61 (24) 13 (5)
12 months
Best care
5 point reduction 84 (34) 148 (60) 16 (6)
30% change 139 (56) 82 (33) 27 (11)
Spinal manipulation
5 point reduction 125 (46) 133 (49) 15 (5)
30% change 187 (68) 62 (23) 24 (9)
Exercise and spinal manipulation
5 point reduction 115 (45) 133 (52) 9 (4)
30% change 180 (70) 57 (22) 9 (4)Page 6 of 10
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not an unusual finding. [33,36] The baseline RMDQ score
significantly explained 2% of the residual variance in tran-
sition rating in the regression models we fitted. However,
this is a trivial proportion. In addition, we found the cor-
relation between the follow-up score and the transition
question was greater than the correlation between the
change score and the transition question. These findings
suggest that participants' health status at the time of fol-
low-up may have been the prime driver of their response
to the transition question.
The poor performance of the transition question may
have led to inaccurate estimates of MIC and minimal
detectable change, as both of these rely upon the transi-
tion rating to identify improved or stable patients. How-
ever, our estimated MIC value of 4.0 points, falls within
the 3.0 to 5.0 range of values reported in other studies
using similar methods; [19,22-27] and our minimal
detectable change estimate of 8.1 points, falls between the
5.4 to 12.1 range seen in other studies. [19,20,22-24,37]
Moreover, both our MIC and minimal detectable change
estimates fall within the 2.0 to 8.6 point range considered
by the consensus study team. [28] Therefore, notwith-
standing the questionable performance of our transition
question, we applied the 5 point RMDQ consensus
threshold to our population.
Figure 1 shows the distributions of score change for dete-
riorated, stable and improved patients; it shows that the
mean score change in patients who reported deterioration
on the health transition question is close to zero. The MIC
cut-off point for the highest combination of sensitivity
and specificity corresponded to an improvement in
RMDQ score, rather than a deterioration as one might
expect. This suggests some degree of construct mismatch:
participants may have learned to cope with their disability
better, even though globally, they felt that their back pain
deteriorated. Therefore we adopted the consensus magni-
tudes we used to define improvement, as proxy magni-
tudes for deterioration; however, we acknowledge that
magnitudes for deterioration may not mimic those for
improvement.
Other authors have considered using NNT to report con-
tinuous outcome measures. [7,35,38,39] However, the
methods propounded either base NNT calculations on
group differences, [35,38,39] do not consider measure-
ment error, [7,39] do not consider deteriorations, [38,39]
or are not conducive to the derivation of confidence inter-
vals. [7] Calculating NNT from individual improvements,
rather than group differences, may more accurately
describe the effects of treatment, especially when treat-
ment response is heterogeneous. We have shown that the
measurement error can be considered and incorporated
into consensus of the change threshold. This threshold is
therefore neither MIC, which can be estimated empirically
from valid anchors (such as correctly functioning transi-
tion questions), nor the minimally detectable change,
which can be estimated from a variety of distribution
methods (although we favour the method described in
Additional File 1[20,32]), but a hybrid of these two prop-
erties. A potential weakness of the approach we present to
generating this hybrid is its reliance on expert consensus
to define the thresholds for individual change. Neverthe-
less, NNT has been shown to be remarkably robust to
small variations in thresholds. [6]
One drawback of using NNT is that statistical power is lost
when converting scales to binary outcomes. [7] By virtue
of the large sample sizes in UK BEAM, we were generally
able to report NNTs with confidence intervals of reasona-
ble widths. Although the simpler Wald method produces
confidence intervals that are almost identical to those pre-
sented, we prefer confidence intervals derived from Wil-
son scores; [34] using Wald confidence intervals in studies
with smaller sample sizes, or when NNTs are greater than
10 may result in aberrations or be too narrow. [34]
Table 3: NNTs derived from consensus thresholds for MIC for the RMDQ (95% CI)
Exercise Manipulation Combined
Three months
Improvement, 5 points 8.2 (4.9 to 25.0) 5.2 (3.7 to 8.8) 4.8 (3.5 to 7.8)
Improvement, 30% 9.0 (5.0 to 44.5) 5.4 (3.8 to 9.9) 4.4 (3.3 to 7.0)
Benefit, 5 points 6.6 (4.1 to 16.6) 5.1 (3.6 to 9.3) 4.3 (3.1 to 7.0)
Benefit, 30% 5.1 (3.4 to 10.7) 5.0 (3.4 to 9.8) 3.3 (2.5 to 4.9)
12 months
Improvement, 5 points * - 8.4 (5.0 to 28.6) 9.0 (5.2 to 37.8)
Improvement, 30% * - 8.0 (4.9 to 24.3) 7.1 (4.5 to 17.9)
Benefit, 5 points * - 7.8 (4.5 to 29.0) 7.2 (4.3 to 22.8)
Benefit, 30% * - 6.9 (4.1 to 21.1) 5.8 (3.7 to 13.2)
* Analyses were not performed as no mean difference was reported between the exercise and best care groups at 12 monthsPage 7 of 10
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which vary within persons as well as between persons, an
NNT of four may indicate that 25% of patients are likely
to benefit whenever the treatment is used or that all
patients will benefit 25% of the time. Thus, we cannot iso-
late individual patients who will benefit using this
method; but this does not minimise the usefulness of
NNT in aiding decisions about treatment use at a popula-
tion level.
Wu and Kottke draw attention to other general limitations
of NNT. [41] They show that it can be misleading to com-
pare NNTs from different populations, using the example
of an intervention for lowering serum cholesterol, which
for preventing mortality, has an NNT around 1000 times
larger than the NNT for cardiac transplantation. Thus, the
intervention for lowering serum cholesterol appears to
have a trivial effect compared to cardiac transplantation,
and one may be inclined to believe cardiac transplanta-
tion to be the more useful technology. However, the first
NNT estimate pertains to the entire national population,
whereas the second pertains to a population of cardiac
transplant candidates. At the level of the entire popula-
tion, the intervention for lowering serum cholesterol
would have an impact on death rates five times greater
than cardiac transplantation.
Wu and Kottke also point out that NNT is dependent on
time. Consider that at four weeks the proportion of back
pain patients improving in treatment group A is 20% and
in treatment group B it is 10%; the relative risk is 0.5, and
the NNT is 10. However, at six months if the proportion
improving in group A is 40% and in group B it is 20%; the
relative risk is still 0.5, but the NNT becomes five. Com-
parisons across non-related time points can mislead. We
agree with Gorouhi, that it is necessary to specify a time
period in order to correctly interpret the NNT. [42]
We used the transition question to help us identify partic-
ipants who remained stable between baseline and four
weeks in an attempt to estimate the population-specific
minimal detectable change. This has certain methodolog-
ical shortcomings. Norman et al, [43] caution against ret-
rospective classification of participants as improved or
stable based on a transition question, explaining that it is
possible for this to be unrelated to treatment effect. Also,
as discussed above, participants' selection of 'No change'
may be guided more by their health state at the time,
which was subject to within person variation, than by
their aggregate change since first measurement. In this
study, participants who selected 'No change' on the tran-
sition question at four weeks had decreasing RMDQ
scores. In light of this, we must consider that our popula-
tion-specific estimate of minimal detectable change could
be inaccurate, and we recommend that in future, this
method of retrospectively identifying stable participants is
generally avoided.
A number of our analyses were subject to floor and ceiling
effects. For example using five points to define an impor-
tant change, means that a patient with a RMDQ score of
four (the lowest score permitted in UK BEAM) could not
have reached the improvement threshold and patients
with scores of greater than 19 could deteriorate. Similarly,
when using the 30% change threshold, although there
was no floor effect, participants with scores higher than 18
could not deteriorate. Sensitivity analyses (not presented
here) allowing for these effects, produced results similar
to our main analyses.
Whilst not wanting to make too much of a post-hoc re-
analysis of these data, it is clear that the small NNTs we
derived might, if confirmed, make manipulation very
attractive to clinicians, patients, and purchasers. This is an
important and new observation.
We have demonstrated that patient-reported continuous
outcomes can be reported as NNTs; these aid interpreta-
tion. US Food and Drug Administration guidance states
that when clinical trials show small mean effect sizes it
may be more informative to look at individual rather than
group responses. [44] It also states that the definition of
an individual 'responder' should be based on pre-speci-
fied criteria backed by empirically derived evidence. Fol-
lowing consensus on appropriate thresholds of individual
change, analysis in the manner we describe is both facili-
tated and the logical next step. This raises the extremely
important question, as to whether reporting results in this
way should be the norm in trials assessing disorders with
chronic variable courses such as depression, back pain or
chronic fatigue. If the same pattern we have shown here
was seen in trials of Selective Serotonin Reuptake Inhibi-
tors, then in contrast with the conclusions of Kirsch and
colleagues, [2] we might conclude that they were good
enough to justify their routine use for mild to moderate
depression.
Future agreement on thresholds for deterioration would
permit the estimation for NNT for benefits gained and a
more comprehensive picture of the effect of treatment
could be portrayed. In some instances, especially where
desirable correlations can be established between the
HRQoL measure and the transition question, the transi-
tion question may be useful and aid interpretation of out-
comes.
Finally, it is not our intention to suggest reporting contin-
uous outcomes using NNT should replace conventional
analysis, which is necessary to ensure between-group dif-
ferences are statistically significant rather than chancePage 8 of 10
(page number not for citation purposes)
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analyses are complementary and aid clinical interpreta-
tion. [7]
Conclusion
In contrast to the small mean differences originally
reported, NNTs were small and could be attractive to cli-
nicians, patients and purchasers. How results of clinical
trials are presented could have important implications for
how they are interpreted, and how their findings are
implemented. Reporting outcomes of clinical trials using
mean differences may not give a full picture of the effect
of treatments on patient health, especially when the
response to treatment is heterogeneous. Reporting the
NNT is currently challenging due to difficulties in defining
thresholds of individual improvement that encompass
both within patient variation/measurement error and
clinically important change. Where possible, trialists
should consider reporting NNTs alongside mean differ-
ences to aid interpretation.
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